Thyroid eye disease (TED) therapy Tepezza – the best asset in Amgen's $26 billion takeover of Horizon in 2023 – could be struggling with Levels of competition from an easier-to-dose choice from Sling Therapeutics. The inflammation can drive the eyes forward or trigger the eyes and